ImmunoGen (IMGN) Shares Gap Up Following Strong Earnings
Shares of ImmunoGen, Inc. (NASDAQ:IMGN) gapped up prior to trading on Friday following a stronger than expected earnings report. The stock had previously closed at $4.82, but opened at $5.14. ImmunoGen shares last traded at $5.67, with a volume of 3778150 shares changing hands.
The biotechnology company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. ImmunoGen had a negative net margin of 176.35% and a negative return on equity of 673.66%. The company had revenue of $13.79 million during the quarter, compared to the consensus estimate of $12.42 million. During the same quarter last year, the firm posted ($0.11) EPS. The company’s quarterly revenue was down 65.0% on a year-over-year basis.
A number of research firms have recently issued reports on IMGN. ValuEngine upgraded shares of ImmunoGen from a “hold” rating to a “buy” rating in a research note on Wednesday, October 17th. BidaskClub cut shares of ImmunoGen from a “hold” rating to a “sell” rating in a research note on Wednesday, October 24th. William Blair restated an “outperform” rating on shares of ImmunoGen in a research note on Monday, October 22nd. Piper Jaffray Companies set a $14.00 target price on shares of ImmunoGen and gave the stock a “buy” rating in a research note on Sunday, December 2nd. Finally, HC Wainwright set a $18.00 target price on shares of ImmunoGen and gave the stock a “buy” rating in a research note on Tuesday, November 6th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $14.60.
The company has a current ratio of 4.59, a quick ratio of 4.56 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $845.34 million, a price-to-earnings ratio of -7.56 and a beta of 2.36.
TRADEMARK VIOLATION WARNING: “ImmunoGen (IMGN) Shares Gap Up Following Strong Earnings” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2019/02/09/immunogen-imgn-shares-gap-up-following-strong-earnings.html.
About ImmunoGen (NASDAQ:IMGN)
ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.
Recommended Story: How analysts view the yield curve
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.